Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.84 |
| ▸ | NPC1 | O15118 | 9/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.66 |
| ▸ | MLYCD | O95822 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029008 | 0.94 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL14020485 | 0.90 | NPC1 (0.92) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL24649289 | 0.87 | MAPT (0.70) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL25137055 | 0.85 | MAPT (0.68) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL104431 | 0.84 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL14456669 | 0.84 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL19226497 | 0.84 | LMNA (0.64) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL751214 | 0.84 | HDAC2 (0.80) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL10761716 | 0.83 | HDAC2 (0.73) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 | |
| SCHEMBL16900376 | 0.83 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | RAB9A 3030/4885NPC1 1892/4885SMN1; SMN2 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.